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ABSTRACT
After allogeneic hematopoietic cell transplantation (HCT), the high inverse correlation between graft-versus-host
disease (GVHD) and leukemic relapse requires that calculated measures be taken to reduce GVHD pathology while
retaining the graft-versus-leukemia (GVL) effect. We sought to determine whether donor CD4CD25 regulatory
T cells could control ongoing GVHD, thereby providing an initial window of time in which the alloreactive
anti-host response is permitted to begin, with the intent of most effectively eliminating residual leukemia cells.
Prevention of lethal GVHD by infusion of donor CD4CD25 cells early after HCT (day 2) was achieved across
a major histocompatibility complex barrier in the haploidentical C3H3(B6xC3H)F1 model. However, in vitro
expansion of donor CD4CD25 T cells, stimulated by recipient cells in the presence of high-dose interleukin-2,
was required for successful regulation. In contrast, in the major histocompatibility complex–matched, minor
histocompatibility antigen–disparate, CD8-mediated B10.BR3CBA GVHD model, lethal disease could be com-
pletely prevented by a single infusion of freshly isolated donor CD4CD25 cells administered as late as 10 days
after HCT. Of importance, this late regulatory effect required only a 3:1 ratio of effector CD8:CD4CD25T cells,
indicating a strong potential for the delayed infusion of CD4CD25 cells to control GVHD across minor
histocompatibility antigen barriers. Furthermore, this regulation did not interfere with complete and lasting donor
engraftment of the hematopoietic compartment. Of most significance, the day 10 infusion of donor CD4CD25
cells into CBA HCT recipients that had been challenged with the MMCBA6 myeloid leukemia cell line did not
block an effective GVL response, despite reducing lethal GVHD. These results suggest that donor CD4CD25
T cells infused soon after transplantation can ameliorate the development of GVHD without sacrificing a sufficient
GVL effect.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
The application of allogeneic hematopoietic cell
transplantation (HCT) as treatment for a number of
otherwise fatal hematologic malignancies is limited by
the excessive incidence of graft-versus-host disease
(GVHD). The high inverse correlation between
GVHD and leukemic relapse, however, requires that
very calculated measures be taken to minimize the
former without sacriﬁcing the critical graft-versus-
leukemia (GVL) effect. A potential approach that may
permit a limited and controlled alloreactive anti-host
reaction to provide an effective GVL response is the
application of CD4CD25 regulatory T cells.
A unique subset of thymus-derived CD4 T cells
was found to constitutively express the interleukin
(IL)-2 receptor  chain (CD25) and exhibited potent
immunoregulatory properties [1]. These CD4CD25
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T cells were hypothesized to serve as a safeguard
against the activation of autoreactive T cells that es-
cape deletion in the thymus, possibly by blocking their
production of IL-2 [2-4]. An interesting feature of
CD4CD25 regulatory T cells is that despite being
classically anergic to T-cell receptor (TCR) stimula-
tion in vitro, this ligation is required to allow them to
mediate their immunosuppressive function [5]. Fur-
thermore, once activated, these cells are antigen non-
speciﬁc with regard to the T-cell responses that they
are able to suppress [5].
Investigations into the parameters that affect the
development and diversity of the CD4CD25T-cell
repertoire have provided insight into their potential
roles in the regulation of the immune system [4,6,7].
Experiments with dual transgenic mice, expressing
both a speciﬁc TCR and the thymic expression of the
cognate peptide suggested that thymic regulatory T-
cell generation is dependent on high-afﬁnity interac-
tions between the TCR and the peptide-major histo-
compatibility complex (MHC) class II complex during
T-cell maturation [6]. Another study compared pe-
ripheral CD4CD25 T-cell numbers across a series
of mice expressing MHC class II molecules occupied
by a range of different self-peptides and found a direct
correlation, supporting the notion that thymic selec-
tion of these cells may resemble that of normal CD4
T cells in repertoire diversity [7]. These results also
were consistent with data that showed a diverse in-
volvement of TCR V and V gene families in the
CD4CD25 T-cell repertoire [4]. This broadness of
the regulatory T-cell repertoire becomes highly rele-
vant in the context of alloreactivity, a phenomenon
driven by cross-reactivity and degeneracy of the T-cell
repertoire [8]. Thus, when activated through the TCR
by alloantigens, CD4CD25 T cells potentially
could be used to actively suppress an alloresponse,
such as in tissue allograft rejection or in GVHD after
allogeneic HCT.
In the case of allograft rejection, alloantigen-spe-
ciﬁc regulation was ﬁrst shown when tolerance to skin
grafts was transferred with the injection of
CD45RBlow CD4 and CD4CD25 T cells but
could only be achieved against grafts from the original
tolerating strain [9,10]. Importantly, it also has been
shown that CD4CD25 T cells can play an active
role in maintaining the anergic phenotype of an allo-
reactive CD8 T-cell population, thus indicating the
immunoregulatory scope of these cells [11].
In the HCT setting, initial observations suggest
that de novo–derived donor CD4CD25 T cells
effectively inhibit the development of GVHD induced
by delayed donor lymphocyte infusion in MHC-hap-
loidentical mice [12]. Moreover, CD4CD25T cells
generated in vitro by incubation of alloreactive cells in
the presence of anti-CD40 ligand antibody are able to
block the development of GVHD when coadminis-
tered with normal alloreactive donor T cells [13]. In
the present study, we conﬁrm that, in the context of an
allogeneic MHC-mismatched bone marrow trans-
plant, rapidly lethal GVHD is prevented when
CD4CD25 T cells from the donor strain are co-
transferred along with the GVHD-inducing CD4 T
cells at time of transplantation.
Of primary interest, the HCT setting is unique in
the case of patients with leukemia because the same
alloreactive donor T cells that mediate GVHD also
may mount a GVL effect [14,15]. The important
question then becomes whether CD4CD25 T cells
can not only prevent GVHD, but whether their de-
layed infusion can be used to ameliorate the develop-
ment of GVHD after it has been initiated, thus pro-
viding an early unrestricted alloreaction for the
beneﬁt of a most effective GVL response. Our data
indicate that donor CD4CD25 T cells may be used
to suppress an early GVHD reaction without sacriﬁc-
ing the therapeutic beneﬁt of an effective GVL re-
sponse.
MATERIALS AND METHODS
Mice
C3H/Hej and B10.BR/SgSn (both H2k) strains
were purchased from the Jackson Laboratory (Bar
Harbor, ME). (B6xC3H)F1(H2
b/k) and CBA mice (ei-
ther JCr or NCr substrains, as available; H2k) were
purchased from the National Cancer Institute Animal
Procurement Program (Frederick, MD). For all ex-
periments, sex-matched mice between the ages of 7
and 14 weeks were used as donors and recipients. Mice
were housed in a pathogen-free environment in auto-
claved microisolator cages and were provided with
autoclaved water and food ad libitum.
Cell Lines and Media
The MMCBA6 cell line is a c-myc retrovirus-
transformed myeloid leukemia cloned from the ascites
of CBA mice that had been injected with a c-myc–
encoding moloney murine leukemia virus construct, as
previously described [16]. The line was grown in com-
plete media: RPMI 1640, supplemented with 2
mmol/L of L-glutamine, 50 IU/mL of penicillin, 50
g of streptomycin (all from Mediatech, Herndon,
VA), 10% fetal calf serum (Sigma Chemical, St. Louis,
MO), and 2-mercaptoethanol (Life Technologies,
Grand Island, NY), at 37°C in 7% CO2.
Monoclonal Antibodies
Ascites ﬂuid containing anti-Thy-1.2 (J1j: rat im-
munoglobulin (Ig)M [17]), anti-CD8 (3.168; rat IgM
[18]), or anti-CD4 (RL172; rat IgM [19]) monoclonal
antibodies (mAbs) were used along with guinea pig
complement (C; Rockland, Boyertown, PA) for cell
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subset depletions. Afﬁnity-puriﬁed goat anti-mouse
IgG antibody (Cappel-Organon Teknika, West Ches-
ter, PA) was used for B-cell panning. For donor chi-
merism analysis and phenotypic analysis of donor
grafts, ﬂuorescein isothiocyanate (FITC) and/or phy-
coerythrin (PE)-labeled mAbs speciﬁc for the follow-
ing determinants were used: irrelevant isotype control,
Ly9.1, H2Kk, CD3, CD4, CD8, B220, CD11b
(MAC-1), and CD11c (all from Pharmingen, San Di-
ego, CA). For CD25 cell selection, FITC- or PE-
conjugated anti-CD25 mAbs (clones 7D4 and PC61,
respectively; Pharmingen) were used.
Flow Cytometry
Between 0.06 to 0.125 g of each mAb was incu-
bated with 1  106 cells in phosphate buffered
saline (PBS) containing 1% bovine serum albumin and
0.01% NaN3 (wash buffer) for 25 minutes at 4°C.
After multiple washes in wash buffer, ﬂuorescence
analysis was either performed immediately or cells
were ﬁxed in 1% paraformaldehyde (Electron Micros-
copy Sciences, Ft. Washington, PA) for 15 minutes at
4°C, followed by a ﬁnal wash. Fluorescence analysis
was performed on a Beckman Coulter XL-MCL an-
alytic cytometer (Beckman Coulter, Miami, FL). Flow
cytometric gates were established by excluding back-
ground isotype-control Ab binding. In the case of
two-color staining, individual populations of control
cells were stained with positive control PE and FITC-
labeled antibodies, respectively, to assure no back-
ground overlap in ﬂuorescence emission between the
two ﬂuorochromes.
Preparation of Donor Cells
PBS (BioWhittaker, Walkerville, MD), supple-
mented with 0.1% BSA (Sigma Chemical), was used
for all preparative manipulations of the donor bone
marrow and lymphocytes. Antibody T-cell–depleted
bone marrow (ATBM) was prepared by ﬂushing bone
marrow cells from the femurs and tibiae of donor
strain mice, followed by incubation with J1j mAb (1:50
dilution) and C (1:12 dilution) for 45 minutes at
37°C. T-cell–enriched donor cells were prepared
from pooled spleen and lymph node (LN) cell suspen-
sions from donor mice as previously described [20].
Brieﬂy, after red blood cell lysis with Gey’s balanced
salt solution containing 0.7% NH4Cl, B cells were
removed by panning the cell suspension over goat
anti-mouse IgG-coated plastic petri dishes for 1 hour
at 4°C. In some experiments, nonadherent lympho-
cytes were depleted of CD4 or CD8 T cells using
incubation with the appropriate mAb (1:50-1:100 di-
lution) and C (1:12 dilution) for 45 minutes at 37°C.
Donor T cells were 96% enriched for subset of
interest, as determined using ﬂow cytometry. For sep-
aration of CD4CD25 cells: following the labeling
of donor CD4 T cells with FITC- or PE-conjugated
anti-CD25 mAb (0.06–0.1 g of Ab/106 cells), cells
were incubated with immunomagnetic cell sorting
anti-FITC or anti-PE microbeads, respectively
(Miltenyi Biotec, Berisch-Gladbach, Germany). La-
beled cells were then positively selected by the Vario
MACS column system as per manufacturer’s instruc-
tions (Miltenyi). Mean purity of positively selected
CD25 cells ranged between 85% and 93% with
93% being CD4. Cells were injected intravenously
(i.v.) in PBS alone.
CD4CD25 In Vitro Expansion
Culture conditions were adapted from a previously
published protocol [5]. Brieﬂy, after separation, donor
CD4CD25 or CD25- cells were resuspended in
complete media and placed into culture with irradi-
ated (20 Gy) recipient splenocytes (1:2 ratio of re-
sponder to stimulator) plus 100 U/mL of recombinant
human IL-2 (NIH AIDS Research and Reference Re-
agent Program, Rockville, MD) for 3 days (37°C, 7%
CO2) and were then cultured in media plus IL-2 alone
for an additional 3 to 4 days. After expansion, the
CD25 culture was 84% to 97% CD25, of which
92% to 98% were CD4.
MLR Culture
Donor CD4 T cells, fresh, or in vitro expanded
CD4CD25 or CD25- T cells were isolated as de-
scribed above. Respective donor T-cell subsets were
then placed into at least triplicate culture, in complete
RPMI, with irradiated (20 Gy) recipient splenocytes
(at 1:1 or 1:2 ratio of responder to stimulator) or were
added into mixed lymphocyte reaction culture in ti-
trated numbers to achieve the indicated responder:
CD25 ratio. Proliferation was assessed on days 3 to 5
of culture by pulsing with 1 Ci/well [3H]-thymidine
(TdR) for 8 hours, and measuring the incorporation
levels from harvested cells with a 1205 Betaplate
counter (Wallac, Turku, Finland). Data are expressed
either as mean [3H]-TdR incorporation counts per
minute (CPM) or mean % suppression of cell prolifer-
ation, calculated as follows: 100% – (mean CPM MLR
with CD25/- / mean CPM untreated MLR * 100).
In Vivo Analysis for GVHD and GVL Responses
C3H (H2k)3(B6xC3H)F1 (H2
k/b) and B10.BR
(H2k3CBA (H2k) bone marrow transplantations
were performed as previously described, with some
modiﬁcations [20]. (B6xC3H)F1 and CBA recipients
were lethally irradiated with 13 Gy, split dose (6.5 Gy
at 1.36 Gy/min) from a 137Cs source (Mark-1 Model
68 gamma irradiator; J.L. Shephard, San Fernando,
CA) and were injected i.v. 4 to 6 hours later with an
appropriate C3H or B10.BR donor inoculum of 1 to
2  106 ATBM cells, alone, or in combination with
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various numbers of naive donor CD4, CD8, and/or
CD4CD25 or CD25- T cells. Some recipients re-
ceived freshly isolated or in vitro expanded donor
CD4CD25 or CD25- cells at either 2, 4, or 10 days
posttransplantation. In experiments meant to study
GVL activity, select groups of CBA recipients were
injected intraperitoneally (i.p.) 1 day before transplan-
tation with 1.5  105 MMCBA6 tumor cells. Animals
were monitored for morbidity and mortality and
weighed regularly until the termination of the exper-
iment. Death from leukemic relapse was determined
by the observation of massive abdominal edema, leu-
kemia cell inﬁltrated ascities, or solid tumor masses at
the time of death, in conjunction with the lack of
clinical and/or histological signs of acute GVHD. Ob-
servations of acute weight loss, hunched posture, di-
arrhea, runted appearance, and consideration of his-
tological evidence from tissue harvested at time points
leading up to or at the time of death indicated death
due to GVHD.
Histology
Sequential ear biopsy specimens were collected
from mice at speciﬁc time points, or collected (along
with tongue, liver, and gut) on humane killing of the
animal when determined to be moribund (when ani-
mals were no longer mobile or were incapable reach-
ing food and water) and prepared for routine histo-
logical analysis [21]. For quantitation of dyskeratotic
epidermal cells, skin samples were evaluated for fea-
tures of apoptotic keratinocytes [21] using light mi-
croscopy by an experienced pathologist without
knowledge of experimental groups. Data is reported as
the mean number of apoptotic keratinocytes per linear
mm (Lmm).
Data Analysis
Median survival times (MST) were calculated as
the interpolated 50% survival point of a linear regres-
sion through all of the death data points, including
zero. Statistical comparisons for survival between ex-
perimental groups are based on days of death post-
transplantation, and were performed using the non-
parametric Wilcoxon signed rank test. Signiﬁcance for
weight comparisons was determined by the t test at
individual time points.
RESULTS
In Vitro Regulation by Naive versus In Vitro
Expanded CD4CD25 T Cells
The ﬂow cytometric proﬁle of the CD4 T-cell
population from combined spleen and LN of naive
C3H mice indicated that approximately 5% of the
gated CD4 T-cell population expressed the CD25
cell surface protein (Figure 1A), consistent with pub-
lished observations [4]. After immunomagnetic cell
sorting, the mean purity of positively selected CD25
cells ranged from 85% to 93%, of which 93% were
CD4 (Figure 1B).
We ﬁrst assessed the ability of donor-derived
CD4CD25 T cells to inhibit an in vitro allogeneic
MLR using a haploidentical strain combination. First,
either whole CD4, CD4CD25, or CD4CD25-
T cells from naive C3H mice were placed into culture
for 3 days with irradiated (20 Gy) (B6xC3H)F1
splenocytes. Consistent with data from other in vitro
models [3-5], CD4CD25 T cells did not proliferate
in response to allogeneic stimulation when compared
with the robust responses of whole CD4 and
CD4CD25- T cells (Figure 1C). Furthermore,
freshly isolated C3H CD4CD25T cells suppressed
alloantigen-driven proliferation of CD4CD25- T
cells by 83.5% at a 2:1 ratio (responder:CD25), de-
creasing to only 17.6% inhibition at a 4:1 ratio (Figure
1D). Based on the observation by Thornton and She-
vach that CD4CD25 cells have more potent sup-
pressor activity after expansion in vitro [5], we adapted
a similar stimulation protocol by which C3H
CD4CD25 and CD25- cells were stimulated with
recipient splenocytes (rather than anti-CD3 Ab) in the
presence of high-dose IL-2 (100 U/mL). An initial
experiment showed that these culture conditions were
sufﬁcient to stimulate alloantigen-driven expansion of
CD4CD25T cells, as indicated by a 7-fold increase
in proliferation over IL-2–only controls on day 3 of
culture (measured using 3H-TdR incorporation, data
not shown). On average, approximately 100% of the
number of CD4CD25 T cells initially put into
culture were recovered at the end of the 6-day expan-
sion. These numbers were similar to those reported by
Taylor et al. [22], who reported a 1.5-fold increase in
the CD4CD25 T-cell number after a similar
method of expansion. These in vitro expanded
CD4CD25 T cells were much more capable of
suppression at lower numbers, as indicated by 88.7%
and 70.7% suppression of the MLR response at a 4:1
and 8:1 ratio (responder:CD25), respectively. In
contrast, no suppression of the proliferative response
resulted from the addition of either naive or in vitro
expanded CD4CD25- cells (Figure 1D).
Regulation of GVHD Post-HCT in a Haploidentical
Model
Reﬂecting their inability to proliferate in vitro to
allogeneic stimulation, 5  105 freshly isolated C3H
CD4CD25 T cells were unable to mediate lethal
GVHD (MST 52 days) or cause any disease-associ-
ated cachexia (P  .2, at all time points) when trans-
ferred along with 2  106 C3H ATBM into lethally
irradiated (13 GY, split dose) (B6xC3H)F1 recipients
(Figure 2A and 2B). This was in sharp contrast to the
very rapid onset of lethal GVHD (MST  10 days)
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that was observed on transfer of the same number of
either C3H whole CD4 or CD4CD25- T cells into
equivalently irradiated and ATBM-transplanted recip-
ients (Figure 2A). Most importantly, C3H
CD4CD25 T cells fully suppressed the develop-
ment of CD4-mediated GVHD (100% survival; MST
52 days) when cotransplanted (at a 1:1 ratio) with
5  105 whole C3H CD4 T cells (Figure 2A). Fur-
thermore, the mean % initial body weights posttrans-
plantation were similar to the control ATBM alone
group (P  .4, at all time points; Figure 2B). This
inhibitory activity was unique to the CD25 subset
because mice that received CD4CD25- T cells at a
similar 1:1 ratio with whole C3H CD4 T cells, at
time of transplantation, still succumbed to rapid onset
lethal GVHD (MST  8 days) (Figure 2A).
To begin to determine the capacity of
CD4CD25 T cells to suppress recently initiated
CD4-mediated GVHD in the haploidentical model,
(B6xC3H)F1 mice were lethally irradiated (13 Gy,
split dose) and initially injected with 2  106 ATBM
cells along with 2.5  105 C3H whole CD4 T
cells. On day 2 posttransplantation, CD4 recipients
were administered i.v. either 1  106 freshly iso-
lated or in vitro expanded C3H CD4CD25 or
CD25- T cells. The freshly isolated donor
CD4CD25 T cells were capable of only minimal,
but signiﬁcant, disease regulation on infusion
shortly after CD4-mediated GVHD induction in
this strain combination (MST increases from 8.6 to
17.3 days; P  .004) (Figure 3A). The loss in
regulatory activity of freshly isolated donor
Figure 1. Functionality of CD4CD25T cells in vitro. (A) Percentage of CD25 cells in CD4 gated spleen and LN T cells from naive C3H
mice. (B) Percentage of CD4CD25 cells on reanalysis after representative immunomagnetic cell sorting procedure. (C) Whole C3H CD4,
fresh CD4CD25, or CD25- T cells were isolated as described in Materials and Methods and cultured in triplicate for 3 days with irradiated
(20 Gy) (B6xC3H)F1 splenocytes (1:2 ratio of responder to stimulator) and pulsed with [3H]-TdR for the last 8 hours of culture. Data are
expressed as mean [3H]-TdR incorporation CPM, and are representative of 2 individual experiments. (D) C3H CD4CD25- T cells were
cultured for 5 days with irradiated (20 Gy) (B6xC3H)F1 splenocytes (1:1 ratio of responder to stimulator) along with titrated numbers of freshly
isolated or in vitro expanded C3H CD4CD25 or CD25- T cells to achieve indicated responder: CD25/- ratios, and pulsed with [3H]-TdR
for the last 8 hours of culture. Data are expressed as the mean % suppression of MLR proliferation and are based on quadruplicate samples
from a single in vitro experiment.
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CD4CD25 cells on infusion between days 0 and
2 posttransplantation likely reﬂected the rapid pro-
gression of the alloresponse in this haploidentical
model. On the other hand, the infusion on day 2 of
the same number of in vitro expanded C3H
CD4CD25 T cells completely prevented GVHD
lethality (MST 86 days; P  .005, in comparison
with the untreated whole CD4 T-cell control
group; Figure 3A). Signiﬁcant cachexia (P  .04,
compared with ATBM alone) was only noted up to
3 weeks post-HCT, after which point there was
further amelioration of disease and no signiﬁcant
weight difference for the remainder of the experi-
ment (P  .1 versus ATBM alone; Figure 3B). The
infusion of expanded donor CD4CD25- cells also
provided a slight prolongation of survival (MST of
23 days; P  .02 versus the untreated CD4 T
control). This regulatory effect was not signiﬁcantly
greater than that of day 2 injected fresh
CD4CD25 cells (P  .34). Moreover, sustained
acute GVHD-associated cachexia (P  .01 versus
ATBM, all time points) followed by the eventual
100% mortality of this group indicated much less of
a beneﬁcial regulatory effect than expanded CD25
cells (weight loss, P  .02 expanded CD25 versus
CD25- all time points except for week 1; survival,
P  .02, expanded CD25 versus CD25-) (Figure
3A and Figure 3B). The window of opportunity at
Figure 2. Effect of donor CD4CD25 T cells on development of lethal GVHD when infused on day of transplantation. (B6xC3H)F1 mice
were lethally irradiated (13 Gy, split dose) and were injected with 2 106 C3H ATBM cells alone, or in combination with either 5 105 whole
C3H CD4, fresh CD4CD25, or CD25- T cells. Additional groups of C3H ATBM  whole CD4 (5  105) recipients also received 5 
105 freshly isolated C3H CD4CD25 or CD25- T cells at the time of transplantation. (A) Survival of transplanted recipients. (B) Body
weights for each group normalized as the mean 	 SEM % initial body weight during sequential 1-week periods. The data shown are
representative of 2 separate experiments that showed similar trends with n 
 4 for all groups, except for n 
 5 for CD4CD25 alone and
n 
 8 for whole CD4.
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the given dose level of in vitro expanded regulatory
cells was apparently short, however, because delay-
ing this injection further until day 4 posttransplan-
tation was ineffective, and GVHD developed with
similar kinetics as untreated CD4 T-cell recipients
(Figure 3A).
These data show that regulation of acute, severe
GVHD post-HCT in this haploidentical model is
strongly dependent on the administration of
CD4CD25 T cells very early posttransplantation,
making the management of this alloresponse for the
beneﬁt of a sufﬁcient GVL effect a difﬁcult endeavor.
Thus, we next focused on a generally less aggressive
MHC-matched GVHD model to study the potential
of using CD4CD25 T cells to regulate GVHD at
later times post-HCT.
Post-HCT Regulation of GVHD across a Minor
Histocompatibility Antigen Barrier
Lethally irradiated (13 GY, split dose) CBA (H2k)
recipients underwent transplantation with MHC-
matched, minor histocompatibility antigen (miHA)
disparate B10.BR (H2k) ATBM alone, or along with
3  106 B10.BR CD8 T cells. On either day 2, 4, or
10 posttransplantation, CD8 T-cell transplanted re-
cipients were administered 1 dose of 1  106 freshly
isolated B10.BR CD4CD25 T cells. Signiﬁcantly,
we found that the lethal CD8-mediated GVHD
(MST of 52.4 days) could be suppressed by the donor
CD4CD25 T cells when injected as late as 10 days
posttransplantation (day 2, MST 90 days; data not
shown; day 4, MST 90 days, P  .027; day 10, MST
Figure 3. Regulation of recently induced, CD4 T-cell–mediated lethal GVHD in a haploidentical, irradiation model by delayed infusion of
donor CD4CD25 T cells. Lethally irradiated (13 Gy, split dose) (B6xC3H)F1 mice were injected with 2  106 C3H ATBM cells alone or
in combination with 2.5 105 C3H whole CD4T cells. Two or 4 days posttransplantation, CD4T-cell recipients were either left untreated
or infused with 1  106 freshly isolated or in vitro expanded donor CD4CD25 or CD25- T cells. (A) Survival of recipients who underwent
transplantation. (B) Body weights for each group normalized as the mean	 SEM% initial body weight during sequential 1-week periods. Note
that the increase in values for the “Fresh CD25 day 2” group after the second week reﬂected only 1 surviving animal. Survival and weight
data were pooled from 2 similar experiments with n 
 7 to 10, except for the day 4 infusion (n 
 4).
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90 days, P .018 versus untreated CD8 T control;
Figure 4A). Compiled weight data from pooled exper-
iments showed minor, transient GVHD-associated
cachexia in day 4 infused CD25 recipients (P  .02
compared with the ATBM alone group) during week
5 post-HCT, whereas more pronounced cachexia was
noted in the day 10 CD25 group during weeks 2
through 4 post-HCT (P  .043; Figure 4B). No
signiﬁcant difference in weight loss was noted be-
tween day 4 and day 10 CD4CD25 recipients (P 
.09).
To determine whether regulation of GVHD by
donor CD4CD25 cells affected the establishment
of lasting donor chimerism, spleens were harvested at
the conclusion of the experiment (day 90) from recip-
ient mice. Flow cytometric analysis was performed for
expression of Ly9.1, the presence of which denotes
cells of host CBA origin (Table 1). Importantly, ani-
mals that were rescued from lethal GVHD by injec-
tion of donor regulatory T cells had a higher percent-
age of donor-derived T and B cells compared with
equivalently irradiated recipient mice that received
B10.BR ATBM alone (Table 1). This was consistent
with the notion that infused donor T cells could still
enhance donor chimerism by targeting residual recip-
ient hematopoietic cells.
Regulation of Ongoing GVHD with Concomitant
Leukemia Burden
Experiments were performed to determine
whether the delayed infusion of donor CD4CD25
T cells, to suppress the full pathological development
Figure 4. Regulation of ongoing GVHD by delayed infusion of freshly isolated donor CD4CD25 T cells in a MHC-matched model. CBA
mice were lethally irradiated (13 Gy, split dose) and were injected with 2  106 B10.BR ATBM cells alone, or in combination with 3  106
B10.BR CD8 T cells. On either days 4 or 10 posttransplantation, CD8 T-cell transplanted recipients were either left untreated or infused
with 1  106 freshly isolated B10.BR CD4CD25, or CD25- T cells. (A) Survival of transplanted recipients who underwent transplantation.
(B) Body weights for each group normalized as the mean 	 SEM % initial body weight during sequential 1-week periods. Survival and weight
data were pooled from 3 separate experiments (CD8 T cells alone, n 
 19; days 4 and 10 CD4CD25 cells, n 
 6 and 7, respectively; days
4 and 10 CD4CD25- cells n 
 9 and 9, respectively; ATBM n 
 10).
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of GVHD, compromised an effective GVL response.
CBA mice were challenged i.p. with 1.5  105
MMCBA6 cells (a myeloid leukemia cell line of CBA
origin) 1 day before exposure to lethal irradiation (13
Gy, split dose), followed by i.v. injection with 2  106
B10.BR ATBM cells alone, or in combination with
15  106 B10.BR CD8 T cells. All of the MMCBA6
challenged recipients who were transplanted with
ATBM alone succumbed to leukemia burden by day
28 posttransplantation (Figure 5A), indicated by the
presence of massive abdominal edema, hemorrhagic
ascities, and, in some animals, solid tumor masses
observed at time of death (all hallmarks of tumor cell
burden in this myeloid leukemia model [23]). All mice
injected with only ATBM and B10.BR CD8 T cells
succumbed to GVHD, with an MST of 19.6 days,
Table 1. Regulation of GVHD by the Delayed Infusion of Donor CD4 CD25 T Cells Does Not Sacriﬁce Stable Donor Engraftment
Recipient Group Lymphocyte Subsets
CD3 CD4 CD8 B220
ATBM (n  3) 75.4  5.1 76.4  4.9 80.1  4.7 92.2  6.1
CD8  day 4 CD25 (n  4) 96.0  .9 98.2  .9 97.5  1.4 97.9  .4
CD8  day 10 CD25 (n  3) 98.5  .4 99.4  .15 98.6  .4 98.9  .1
NOTE. At the conclusion of the experiment (day 90), spleens were harvested from lethally irradiated CBA mice that received B10.BR
ATBM alone or in combination with 3  106 CD8 T cells followed by 1  106 B10.BR CD4CD25 T cells on either days 4 or 10
posttransplantation. Dual color ﬂow cytometry was performed for the lymphocyte subset expression of Ly9.1, the presence of which denoted
cells of host origin. Data is expressed as mean % donor chimerism 	 SEM and is representative of 2 individual experiments.
Figure 5. Retention of GVL effect after day 10 posttransplantation infusion of donor CD4CD25 T cells. CBA mice were challenged i.p.
with 1.5  105 MMCBA6 leukemia cells, or left untreated, and in both cases were lethally irradiated the following day (13 Gy, split dose) and
injected with B10.BR ATBM alone, or in combination with 1.5  107 B10.BR CD8 T cells. On day 10 post-HCT, recipients were either
left untreated or infused with 1  106 freshly isolated B10.BR CD4CD25 T cells. (A) Survival of transplanted recipients. (B) Body weights
for each group normalized as the mean 	 SEM % initial body weight during sequential 1-week periods. The data shown are representative
of 2 separate experiments that showed similar trends with n 
 5 for all groups, except CD8 T cell plus MMCBA6, n 
 4.
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whereas those additionally challenged with MMCBA6
leukemia cells also died of apparent GVHD (MST
29.6 days, with no signiﬁcant difference between these
groups; P  .06). In contrast, the day 10 infusion of
donor CD4CD25 T cells allowed for a prolonged
survival with an MST of 64.8 days. Reduced GVHD
target tissue injury was shown by lower apoptotic
keratinocyte counts per Lmm of epidermis from skin
samples harvested on day 35 posttransplantation from
CD4CD25 infused mice compared with untreated
CD8 plus MMCBA6 controls (Figure 6). Further
qualitative histological analysis of skin samples also
showed a greater degree of epithelial hyperplasia and
epidermal T-cell inﬁltration in untreated animals
compared with CD25 recipients (Figure 6). Gross
pathological examination of surviving mice at the con-
clusion of the experiment (day 100) showed restricted
leukemia growth, as indicated by qualitative observa-
tions of either early-stage (low-volume) peritoneal
edema collection or solid tumor growth localized to
the area of the original tumor injection. Furthermore,
these remaining mice showed no signs of clinical
GVHD (ie, cachexia, runted appearance) and had
mean % initial body weights similar to the control
ATBM group by 10 weeks post-HCT (P .09; Figure
5B).
DISCUSSION
A number of different approaches have shown
promise in preclinical studies as a means to achieve the
separation of GVHD development from GVL re-
sponses. These approaches include selective lympho-
cyte subset depletion (CD4, CD8, NK1.1) [23-
25]; in vivo cytokine manipulation [26-30]; treatments
Figure 6. Reduced GVHD target tissue injury in CD4CD25 treated animals. Graphic representation of the number of apoptotic
keratinocytes per Lmm of epidermis day 35 post-HCT. Apoptotic cell counts were taken from 10 mean Lmm of epidermis/sample and
ranged from 1.2 to 2.6 C/Lmm for untreated controls (n 
 2; SEM 
 0.725), 0.2 to 1.2 C/Lmm for CD25 treated animals (n 
 4; SEM 

0.215; P 
 .08 CD25 versus untreated recipients) and 0.06 to 0.3 for ATBM controls (n 
 4; SEM 
 0.048). Panels A to C overlying each
bar display representative and corresponding histopathological changes. Note marked basal cell layer apoptosis (arrows) resulting in zones of
dermal-epidermal separation (*) in CD8 plus MMCBA6 animal (A), with less severe (B) and relatively absent (C) injury in CD8 plus MMCBA6
plus CD25 and ATBM animals, respectively.
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based on effector phenotype differences between
GVHD- and GVL-mediating T-cell populations [31-
34]; and in vivo T-cell depletion posttransplantation
[35,36]. In addition, we have used CDR3-size spectra-
type analysis to identify TCR V families involved in
the anti-tumor but not the anti-host allogeneic re-
sponse, allowing for the successful transfer of T cells
capable of mediating GVL without GVHD [37]. Ar-
guably, however, the most effective GVL response
occurs in the context of GVHD [38-42], taking ad-
vantage not only of tumor alloantigen expression but
also the inﬂammatory environment generated by the
allogeneic reaction. Experimentally, this can be appre-
ciated in the work of Johnson et al. and Drobyski et al,
where they note more effective GVL and increased
donor engraftment after protocols targeted for
GVHD therapy rather than prevention [35,36]. These
data suggest that by controlling the progression of the
allogeneic response posttransplantation, the positive
effects of a GVH reaction can be separated from its
pathological effects. Our current results support this
notion by showing that delayed infusion of donor-
derived CD4CD25 regulatory T cells to the recip-
ient posttransplantation can be used as a means to
ameliorate an ongoing GVHD response without sac-
riﬁcing lasting donor engraftment or a protective
GVL effect.
The use of CD4CD25 T cells in tissue trans-
plantation models has high clinical relevance. Not
only have CD4CD25 cells been found in the thy-
mus and peripheral blood of humans, but they also
appear to have immunoregulatory properties similar
to those observed in experimental models [43-45].
Furthermore, the difﬁculty of isolating signiﬁcant
numbers of these cells from human peripheral blood
(about 3% of total peripheral blood mononuclear
cells) can be overcome by in vitro expansion, a process
that does not forfeit their regulatory function
[5,22,43].
We have shown that freshly isolated donor
CD4CD25 T cells themselves are not capable of
mediating GVHD in the C3H (H2k)3(B6xC3H)F1
(H2k/b) haploidentical, lethal irradiation model. How-
ever, they can prevent lethal GVHD and most asso-
ciated cachexia when administered at a 1:1 ratio (ef-
fector cell:CD25) at the time of transplantation.
Although these ﬁndings support published results
showing prevention of GVHD by infusion of freshly
isolated donor CD4CD25 T cells at the time of
transplantation [46,47], these data contrast with the
ﬁndings of Taylor et al. [13], who reported only a
modest GVHD protective effect mediated by these
cells at a similar 1:1 ratio in the B63bm12 MHC class
II-disparate model. These different observations are
most likely because of variation in the GVHD models
used because their system involved sublethal irradia-
tion without the use of donor bone marrow rescue. B6
T cells were transplanted to bm12 recipients and may
have been able to destroy host stem cells before CD25
regulation could take full effect [13]. In contrast, in
the present study, GVHD-related target organ injury
may occur at a slower pace and, therefore, could come
under better control by the CD25 cells.
Because suppression of the allogeneic response at
the time of transplantation could endanger engraft-
ment facilitating GVH reactions as well as an optimal
GVL effect, we sought to discern whether donor
CD4CD25 cells could still temper GVHD devel-
opment when injected post-HCT. In contrast to in-
fusion at the time of transplantation, we found that
freshly isolated donor CD4CD25 cells were inca-
pable of preventing lethal GVHD in the
C3H3(B6xC3H)F1 model when injected on day 2
posttransplantation, even at a 1:4 ratio (effector cell:
CD25). However, the same number of in vitro ex-
panded CD4CD25 cells completely prevented le-
thal GVHD, likely reﬂecting the markedly enhanced
frequency and regulatory properties of these cells, as
ﬁrst described by Thornton and Shevach [5]. These
data are consistent with the previous ﬁndings of Tay-
lor et al. in the injection of in vitro expanded regula-
tory T cells at the time of transplantation to prevent
GVHD [22].
A small prolongation in overall survival was ob-
served in lethally irradiated (B6xC3H)F1 transplanted
recipients underwent transplantation with C3H
CD4 T cells and infused with donor CD4CD25-
cells on day 2 posttransplantation. Some degree of
regulatory activity by CD25- cells also has been ob-
served in murine experimental autoimmune encepha-
lomyelitis models [48]. In the context of allogeneic
HCT, this small effect might be related to the ob-
served GVHD ameliorating properties of exogenous
IL-2 and IL-12 [49,50] because signiﬁcant amounts of
these cytokines may be produced after the alloactiva-
tion of the infused C3H CD4CD25- cells. Interest-
ingly, B10.BR CD4CD25- cells infused on either day
2, 4, or 10 into recipients of allogeneic CD8 T cells
did not show any regulatory properties and, in fact,
hastened GVHD kinetics. This is consistent with the
lack of inhibitory effects of IL-2 administration in
CD8-mediated GVHD models [51,52].
Despite their enhanced regulatory function, ex-
panded CD4CD25 cells used at a 1:4 ratio (effector
cell:CD25) could not prevent lethal CD4-mediated
GVHD in the C3H3(B6xC3H)F1 model when in-
jected beyond day 2 posttransplantation. In stark con-
trast, lethal GVHD was prevented with a day 10
posttransplantation infusion of freshly isolated donor
CD4CD25 T cells in the MHC matched, CD8-
mediated B10.BR (H2k)3CBA(H2k) model. Clearly,
there are differences in the intensity and severity of
GVHD development between the 2 models, which
could account for the capacity to control disease at a
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later stage in the miHA disparate CD8-mediated
model. On the other hand, in the CD4-mediated
haploidentical model, the most critical period of T-
cell involvement is likely to include their activation,
expansion, and early release of cytokines, such as
INF- and IL-2 [53]. This sets the stage for the rapid
priming and activation of donor/host accessory cells,
such as macrophages, which quickly escalate the in-
ﬂammatory response with the production of large
amounts of TNF-, IL-1, nitric oxide, and IL-12 [53].
Death of the animal soon follows rapid weight loss and
massive diarrhea. In such a scenario, regulatory T cells
would only make a difference in the progression of the
disease early in its development, because it is unlikely
that they would have as signiﬁcant an effect once
accessory cells take on a larger effector cell role. Sup-
port for the concept of a larger accessory cell role in
the C3H3(B6xC3H)F1 model comes from data
showing greater suppression of GVHD lethality by
TNF- neutralizing mAb treatment in this model
than in the B10.BR3CBA strain combination (un-
published data, R. Korngold). Furthermore, the no-
tion of required sustained donor T-cell involvement
during miHA-elicited GVHD is supported by data
showing amelioration of disease across an MHC-
matched barrier after disruption of the alloreactive
T-cell response with anti-CD3 mAb at a late time
point (18 days) post-HCT [35]. Therefore, it is in
models, such as the B10.BR3CBA, where the efﬁcacy
of delayed therapeutic approaches that target alloreac-
tive T cells is likely to be realized.
Achieving reduced GVHD lethality without sac-
riﬁcing a high level of donor engraftment or an effec-
tive GVL response underscores the importance of
being able to control the progression of the anti-host–
speciﬁc T cells posttransplantation. Importantly, the
requirements for regulation of the alloresponse at
later time points may be less stringent than at the time
of HCT because the latter situation involves the sup-
pression of a large bulk of alloreactive cells at once in
the lymphoid compartment, and, perhaps mostly in
the spleen, after intravenous coadministration. In con-
trast, by day 10 in the miHA model studied here,
many of the alloreactive cells may have already under-
gone activation in the lymphoid compartment and
subsequent activation-induced cell death, or have left
to trafﬁc to other peripheral tissue sites, thereby re-
ducing the number of cells in situ to be regulated by
the entering CD4CD25 T cells, and, therefore,
requiring less of them. Another consideration is that
by day 10 post-HCT, most of the lymphoid compart-
ment antigen-presenting cells (APCs) have been killed
by the cytolytic anti-host CD8 T-cell response, thus
preventing the activation of MHC class II restricted
CD4CD25 T cells in the spleen and LNs, and
possibly allowing for more direct trafﬁcking of these
cells to peripheral tissue sites. Stimulation by class II
expressed on activated epithelial cells, endothelial
cells, and professional APCs that have not yet been
targeted, may then follow, leading to direct regulation
of the tissue-lytic alloresponse. We are currently in-
vestigating whether in vitro expanded CD4CD25T
cells could be of even greater use in the miHA system
than freshly isolated cells. Preliminary results suggest
that the frequency of anti-miHA T cells may still be
too low after primary in vitro allo  IL-2 expansion to
make a signiﬁcant difference, thus suggesting that, in
this case, stimulation with anti-CD3 and IL-2 may be
a more effective means of expansion.
During the initiation of GVHD, not all alloreac-
tive mature donor T cells respond at once to alloan-
tigen [54]. Therefore, protocols that limit GVHD by
targeting the alloreactive T-cell response and that
involve pharmaceutical or biochemical agents with
short biological half lives must be administered mul-
tiple times to be continuously present throughout the
development of the alloresponse. The administration
of CD4CD25 T cells to control GVHD has im-
portant advantages over such protocols. First, the ex-
tended survival and proliferation of CD4CD25
cells in vivo, without the loss of regulatory function,
has been shown in lymphopenic hosts [55]. This ex-
tended presence means that regulation of GVHD can
be maintained over the full development of the re-
sponse with one administration of CD4CD25 cells.
Second, the ability of CD4CD25 cells to regulate
the function of activated, as well as naive, T cells has
been shown in an experimental autoimmune model
[56]. Therefore, mature donor T cells that have al-
ready responded to donor alloantigen also may be
subjected to regulation by a subsequent CD4CD25
cell injection. Our data support this observation by
showing control of GVHD development with a day 10
posttransplantation injection of CD4CD25 cells,
by which point, one would expect that most donor
CD8 T cells had already been activated by host
alloantigens. Indeed, in vivo observations of the initial
anti-miHA proliferative response of CD4, as well as
CD8 T cells in the MHC-matched B63BALB.B
strain combination, have indicated that as many as 7
rounds of cell division can occur within 5 days after
transplantation (unpublished data, S. C. Jones and R.
Korngold).
We have yet to fully address questions surround-
ing how the infusion of donor CD4CD25 T cells
might affect reconstitution of general immunity be-
cause the ﬁnding that these cells are capable of anti-
gen-nonspeciﬁc regulation [5] makes this a valid con-
cern. Although the extended survival of CD4CD25
T cells in a lymphopenic environment has been shown
[55], their longevity in MHC-disparate recipients that
have converted to full donor chimerism is question-
able because their survival also has has been shown to
be dependent on recognition of cognate antigen
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[57,58]. In the miHA-disparate situation, however,
there is the potential for continuous allo-stimulation
because even with 100% donor chimerism, radioresis-
tant host stromal tissue is continuously scavenged and
thus class II restricted miHAs can still be presented by
donor-derived APCs to remaining donor CD4CD25
cells.
In conclusion, although a number of uncertainties
remain surrounding the application of CD4CD25
regulatory T cells, the current results provide the
impetus for further investigation into their delayed
infusion to regulate the full pathological development
of GVHD while not sacriﬁcing an effective GVL
response.
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